Activation of PDGFr-β signaling pathway after imatinib and radioimmunotherapy treatment in experimental pancreatic cancer

Michio Abe, Zbigniew P. Kortylewicz, Charles Arthur Enke, Elizabeth Mack, Janina Baranowska-Kortylewicz

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Pancreatic cancer does not respond to a single-agent imatinib therapy. Consequently, multimodality treatments are contemplated. Published data indicate that in colorectal cancer, imatinib and radioimmunotherapy synergize to delay tumor growth. In pancreatic cancer, the tumor response is additive. This disparity of outcomes merited further studies because interactions between these modalities depend on the imatinib-induced reduction of the tumor interstitial fluid pressure. The examination of human and murine PDGFr-β/PDGF-B pathways in SW1990 pancreatic cancer xenografts revealed that the human branch is practically dormant in untreated tumors but the insult on the stromal component produces massive responses of human cancer cells. Inhibition of the stromal PDGFr-β with imatinib activates human PDGFr-β/PDGF-B signaling loop, silent in untreated xenografts, via an apparent paracrine rescue pathway. Responses are treatment- and time-dependent. Soon after treatment, levels of human PDGFr-β, compared to untreated tumors, are 3.4×, 12.4×, and 5.7× higher in imatinib-, radioimmunotherapy + imatinib-, and radioimmunotherapy-treated tumors, respectively. A continuous 14-day irradiation of imatinib-treated xenografts reduces levels of PDGFr-β and phosphorylated PDGFr-β by 5.3× and 4×, compared to earlier times. Human PDGF-B is upregulated suggesting that the survival signaling via the autocrine pathway is also triggered afterstromal injury. These findings indicate that therapies targeting pancreatic cancer stromal components may have unintended mitogenic effects and that these effects can be reversed when imatinib is used in conjunction with radioimmunotherapy.

Original languageEnglish (US)
Pages (from-to)2507-2515
Number of pages9
JournalCancers
Volume3
Issue number2
DOIs
StatePublished - Jun 1 2011

Fingerprint

Radioimmunotherapy
Pancreatic Neoplasms
Neoplasms
Heterografts
Therapeutics
Autocrine Communication
Imatinib Mesylate
Extracellular Fluid
Colorectal Neoplasms
Pressure
Survival
Wounds and Injuries

Keywords

  • Imatinib
  • Pancreatic cancer
  • Pdgf-b
  • Pdgfr-β
  • Radiation
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Activation of PDGFr-β signaling pathway after imatinib and radioimmunotherapy treatment in experimental pancreatic cancer. / Abe, Michio; Kortylewicz, Zbigniew P.; Enke, Charles Arthur; Mack, Elizabeth; Baranowska-Kortylewicz, Janina.

In: Cancers, Vol. 3, No. 2, 01.06.2011, p. 2507-2515.

Research output: Contribution to journalArticle

@article{d8f4b7099f8e45b7a7c4fdf65714c2b0,
title = "Activation of PDGFr-β signaling pathway after imatinib and radioimmunotherapy treatment in experimental pancreatic cancer",
abstract = "Pancreatic cancer does not respond to a single-agent imatinib therapy. Consequently, multimodality treatments are contemplated. Published data indicate that in colorectal cancer, imatinib and radioimmunotherapy synergize to delay tumor growth. In pancreatic cancer, the tumor response is additive. This disparity of outcomes merited further studies because interactions between these modalities depend on the imatinib-induced reduction of the tumor interstitial fluid pressure. The examination of human and murine PDGFr-β/PDGF-B pathways in SW1990 pancreatic cancer xenografts revealed that the human branch is practically dormant in untreated tumors but the insult on the stromal component produces massive responses of human cancer cells. Inhibition of the stromal PDGFr-β with imatinib activates human PDGFr-β/PDGF-B signaling loop, silent in untreated xenografts, via an apparent paracrine rescue pathway. Responses are treatment- and time-dependent. Soon after treatment, levels of human PDGFr-β, compared to untreated tumors, are 3.4×, 12.4×, and 5.7× higher in imatinib-, radioimmunotherapy + imatinib-, and radioimmunotherapy-treated tumors, respectively. A continuous 14-day irradiation of imatinib-treated xenografts reduces levels of PDGFr-β and phosphorylated PDGFr-β by 5.3× and 4×, compared to earlier times. Human PDGF-B is upregulated suggesting that the survival signaling via the autocrine pathway is also triggered afterstromal injury. These findings indicate that therapies targeting pancreatic cancer stromal components may have unintended mitogenic effects and that these effects can be reversed when imatinib is used in conjunction with radioimmunotherapy.",
keywords = "Imatinib, Pancreatic cancer, Pdgf-b, Pdgfr-β, Radiation, Radioimmunotherapy",
author = "Michio Abe and Kortylewicz, {Zbigniew P.} and Enke, {Charles Arthur} and Elizabeth Mack and Janina Baranowska-Kortylewicz",
year = "2011",
month = "6",
day = "1",
doi = "10.3390/cancers3022501",
language = "English (US)",
volume = "3",
pages = "2507--2515",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Activation of PDGFr-β signaling pathway after imatinib and radioimmunotherapy treatment in experimental pancreatic cancer

AU - Abe, Michio

AU - Kortylewicz, Zbigniew P.

AU - Enke, Charles Arthur

AU - Mack, Elizabeth

AU - Baranowska-Kortylewicz, Janina

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Pancreatic cancer does not respond to a single-agent imatinib therapy. Consequently, multimodality treatments are contemplated. Published data indicate that in colorectal cancer, imatinib and radioimmunotherapy synergize to delay tumor growth. In pancreatic cancer, the tumor response is additive. This disparity of outcomes merited further studies because interactions between these modalities depend on the imatinib-induced reduction of the tumor interstitial fluid pressure. The examination of human and murine PDGFr-β/PDGF-B pathways in SW1990 pancreatic cancer xenografts revealed that the human branch is practically dormant in untreated tumors but the insult on the stromal component produces massive responses of human cancer cells. Inhibition of the stromal PDGFr-β with imatinib activates human PDGFr-β/PDGF-B signaling loop, silent in untreated xenografts, via an apparent paracrine rescue pathway. Responses are treatment- and time-dependent. Soon after treatment, levels of human PDGFr-β, compared to untreated tumors, are 3.4×, 12.4×, and 5.7× higher in imatinib-, radioimmunotherapy + imatinib-, and radioimmunotherapy-treated tumors, respectively. A continuous 14-day irradiation of imatinib-treated xenografts reduces levels of PDGFr-β and phosphorylated PDGFr-β by 5.3× and 4×, compared to earlier times. Human PDGF-B is upregulated suggesting that the survival signaling via the autocrine pathway is also triggered afterstromal injury. These findings indicate that therapies targeting pancreatic cancer stromal components may have unintended mitogenic effects and that these effects can be reversed when imatinib is used in conjunction with radioimmunotherapy.

AB - Pancreatic cancer does not respond to a single-agent imatinib therapy. Consequently, multimodality treatments are contemplated. Published data indicate that in colorectal cancer, imatinib and radioimmunotherapy synergize to delay tumor growth. In pancreatic cancer, the tumor response is additive. This disparity of outcomes merited further studies because interactions between these modalities depend on the imatinib-induced reduction of the tumor interstitial fluid pressure. The examination of human and murine PDGFr-β/PDGF-B pathways in SW1990 pancreatic cancer xenografts revealed that the human branch is practically dormant in untreated tumors but the insult on the stromal component produces massive responses of human cancer cells. Inhibition of the stromal PDGFr-β with imatinib activates human PDGFr-β/PDGF-B signaling loop, silent in untreated xenografts, via an apparent paracrine rescue pathway. Responses are treatment- and time-dependent. Soon after treatment, levels of human PDGFr-β, compared to untreated tumors, are 3.4×, 12.4×, and 5.7× higher in imatinib-, radioimmunotherapy + imatinib-, and radioimmunotherapy-treated tumors, respectively. A continuous 14-day irradiation of imatinib-treated xenografts reduces levels of PDGFr-β and phosphorylated PDGFr-β by 5.3× and 4×, compared to earlier times. Human PDGF-B is upregulated suggesting that the survival signaling via the autocrine pathway is also triggered afterstromal injury. These findings indicate that therapies targeting pancreatic cancer stromal components may have unintended mitogenic effects and that these effects can be reversed when imatinib is used in conjunction with radioimmunotherapy.

KW - Imatinib

KW - Pancreatic cancer

KW - Pdgf-b

KW - Pdgfr-β

KW - Radiation

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=79959685875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959685875&partnerID=8YFLogxK

U2 - 10.3390/cancers3022501

DO - 10.3390/cancers3022501

M3 - Article

C2 - 24212821

AN - SCOPUS:79959685875

VL - 3

SP - 2507

EP - 2515

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 2

ER -